$1.84 EPS Expected for PetroChina Company Limited (ADR) (PTR); Cmt Asset Management LTD Has Raised Its Bristol Myers Squibb Co (BMY) Stake

August 2, 2017 - By wolcottdaily

Analysts expect PetroChina Company Limited (ADR) (NYSE:PTR) to report $1.84 EPS on August, 23.They anticipate $0.59 EPS change or 47.20% from last quarter’s $1.25 EPS. PTR’s profit would be $6.01B giving it 8.77 P/E if the $1.84 EPS is correct. After having $0.44 EPS previously, PetroChina Company Limited (ADR)’s analysts see 318.18% EPS growth. About 53,900 shares traded. PetroChina Company Limited (ADR) (NYSE:PTR) has risen 2.18% since August 2, 2016 and is uptrending. It has underperformed by 14.52% the S&P500.

Cmt Asset Management Ltd increased Bristol Myers Squibb Co (BMY) stake by 11.6% reported in 2016Q4 SEC filing. Cmt Asset Management Ltd acquired 9,519 shares as Bristol Myers Squibb Co (BMY)’s stock declined 1.04%. The Cmt Asset Management Ltd holds 91,562 shares with $5.35M value, up from 82,043 last quarter. Bristol Myers Squibb Co now has $91.09 billion valuation. The stock declined 1.01% or $0.57 reaching $55.54 on the news. About 1.76 million shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since August 2, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Since February 27, 2017, it had 1 insider purchase, and 6 insider sales for $9.91 million activity. $282,470 worth of Bristol-Myers Squibb Co (NYSE:BMY) was sold by Schmukler Louis S. The insider Caldarella Joseph C sold $463,779. Samuels Theodore R. II bought $681,240 worth of stock. ANDREOTTI LAMBERTO sold $1.81 million worth of stock. Shares for $5.27 million were sold by LEUNG SANDRA on Friday, March 3.

Investors sentiment decreased to 0.97 in Q4 2016. Its down 0.16, from 1.13 in 2016Q3. It worsened, as 86 investors sold BMY shares while 529 reduced holdings. 126 funds opened positions while 468 raised stakes. 1.14 billion shares or 1.92% more from 1.12 billion shares in 2016Q3 were reported. Amer Research reported 2,090 shares. Jpmorgan Chase & Company invested 0.41% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Independent holds 1.34% or 49,520 shares in its portfolio. Associated Banc accumulated 241,521 shares. Essex invested in 72,302 shares. Wagner Bowman Mgmt Corporation holds 0.37% or 19,046 shares. Coastline Company reported 0.31% in Bristol-Myers Squibb Co (NYSE:BMY). Dixon Hubard Feinour & Brown Va invested 1.2% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Howe & Rusling Incorporated holds 54,989 shares. Davenport And Comm Ltd Com invested 0.97% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). 11,084 are held by Savant Ltd Limited Liability Company. Intersect Lc invested in 15,355 shares. Cordasco Fincl reported 343 shares. 1.66M are held by Pictet Asset Mgmt Limited. Sol Capital Mngmt Co reported 22,022 shares stake.

Cmt Asset Management Ltd decreased United States Oil Fund Lp (Put) stake by 123,600 shares to 664,200 valued at $7.78M in 2016Q4. It also reduced Halliburton Co (Put) stake by 19,800 shares and now owns 45,200 shares. Vale S A (Put) was reduced too.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 48 analyst reports since July 28, 2015 according to SRatingsIntel. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, September 9 report. As per Monday, January 25, the company rating was downgraded by BMO Capital Markets. Piper Jaffray upgraded Bristol-Myers Squibb Co (NYSE:BMY) on Monday, August 24 to “Underweight” rating. On Monday, July 17 the stock rating was maintained by Deutsche Bank with “Hold”. UBS maintained the stock with “Buy” rating in Friday, August 19 report. On Tuesday, September 20 the stock rating was maintained by Citigroup with “Buy”. Cowen & Co maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Monday, July 10. Cowen & Co has “Hold” rating and $6500 target. UBS maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Friday, April 29. UBS has “Buy” rating and $80 target. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Buy” rating given on Wednesday, December 2 by Guggenheim. Morgan Stanley downgraded Bristol-Myers Squibb Co (NYSE:BMY) on Friday, August 5 to “Equal-Weight” rating.